ABAlex R. Bautista

Alex R. Bautista

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alex R. Bautista has a total of 73 co-authors. Here are the top co-authors by number of shared publications:

  • Andrew A. Sproul

    Taub Institute for Research on Alzheimer's Disease and the Aging Brain Columbia University Irving Medical Center (CUIMC) New York New York USA

    3 shared publications
  • John F. Tuddenham

    Center for Translational & Computational Neuroimmunology, Neuroimmunology Division, Department of Neurology and the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, United States

    3 shared publications
  • Philip Lawrence De Jager

    Center for Translational & Computational Neuroimmunology, Department of Neurology and the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York, USA

    3 shared publications
  • Ronak Patel

    Department of Pathology and Cell Biology and the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Irving Medical Center

    3 shared publications
  • Verena Haage

    Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, USA

    3 shared publications
  • Alice Buonfiglioli

    Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    2 shared publications

Latest Publications

  • Open Access

    A proteogenomic tool uncovers protein markers for human microglial states

    by Verena Haage, Alex R. Bautista, John Tuddenham, Victoria Marshe, Rebecca Chiu, YunDuo Liu, Tsering Lama, Shane S. Kelly, Neelang A. Parghi, Junho Park, et al.

    Human microglial heterogeneity has been largely described using transcriptomic data. Here, we introduce a microglial proteomic data resource and a Cellular Indexing of Transcriptomes and Epitopes by Sequencing panel enhanced with antibodies targeting 17 microglial cell surface proteins (mCITE-Seq). We evaluated mCITE-Seq on HMC3 microglia-like cells, induced-pluripotent stem cell-derived microglia (iMG), and freshly isolated primary human microglia. We identified novel protein microglial markers such as CD51 and relate expression of 101 cell surface proteins to transcriptional programs. This results in the identification and validation of three protein marker combinations with which to purify microglia enriched with each of 23 transcriptional programs; for example, CD49D, HLA-DR and CD32 enrich for GPNMB high (“disease associated”) microglia. Further, we identify and validate proteins - SIRPA, PDPN and CD162 – that differentiate microglia from infiltrating macrophages. The mCITE-Seq panel enables the transition from RNA-based classification and facilitates the functional characterization and harmonization of model systems.


  • Open Access

    HDAC Inhibitors recapitulate Human Disease-Associated Microglia Signatures in vitro

    by Verena Haage, John F. Tuddenham, Alex Bautista, Charles C. White, Frankie Garcia, Ronak Patel, Natacha Comandante-Lou, Victoria Marshe, Rajesh Kumar Soni, Peter A. Sims, et al.

    Disease-associated microglia (DAM), initially described in mouse models of neurodegenerative diseases, have been classified into two related states; starting from a TREM2-independent DAM1 state to a TREM2 dependent state termed DAM2, with each state being characterized by the expression of specific marker genes 1 . Recently, single-cell (sc)RNA-Seq studies have reported the existence of DAMs in humans 2–6 ; however, whether DAMs play beneficial or detrimental roles in the context of neurodegeneration is still under debate 7,8 . Here, we present a pharmacological approach to mimic human DAM in vitro by exposing different human microglia models to selected histone deacetylase (HDAC) inhibitors. We also provide an initial functional characterization of our model system, showing a specific increase of amyloid beta phagocytosis along with a reduction of MCP-1 secretion. Additionally, we report an increase in MITF expression, a transcription factor previously described to drive expression towards the DAM phenotype. We further identify CADM1 , LIPA and SCIN as DAM- marker genes shared across various proposed DAM signatures and in our model systems. Overall, our strategy for targeted microglial polarization bears great potential to further explore human DAM function and biology.


  • Open Access

    A pharmacological toolkit for human microglia identifies Topoisomerase I inhibitors as immunomodulators for Alzheimer’s disease

    by Verena Haage, John F. Tuddenham, Natacha Comandante-Lou, Alex Bautista, Anna Monzel, Rebecca Chiu, Masashi Fujita, Frankie G. Garcia, Prabesh Bhattarai, Ronak Patel, et al.

    : While efforts to identify microglial subtypes have recently accelerated, the relation of transcriptomically defined states to function has been largely limited to in silico annotations. Here, we characterize a set of pharmacological compounds that have been proposed to polarize human microglia towards two distinct states – one enriched for AD and MS genes and another characterized by increased expression of antigen presentation genes. Using different model systems including HMC3 cells, iPSC-derived microglia and cerebral organoids, we characterize the effect of these compounds in mimicking human microglial subtypes in vitro . We show that the Topoisomerase I inhibitor Camptothecin induces a CD74 high /MHC high microglial subtype which is specialized in amyloid beta phagocytosis. Camptothecin suppressed amyloid toxicity and restored microglia back to their homeostatic state in a zebrafish amyloid model. Our work provides avenues to recapitulate human microglial subtypes in vitro , enabling functional characterization and providing a foundation for modulating human microglia in vivo .


  • Direct Comparison of Epifluorescence and Immunostaining for Assessing Viral Mediated Gene Expression in the Primate Brain

    by Tierney B. Daw, Hala G. El-Nahal, Michele A. Basso, Elizabeth J. Jun, Alex R. Bautista, R. Jude Samulski, Marc A. Sommer, Martin O. Bohlen

    Viral vector technologies are commonly used in neuroscience research to understand and manipulate neural circuits, but successful applications of these technologies in non-human primate models have been inconsistent. An essential component to improve these technologies is an impartial and accurate assessment of the effectiveness of different viral constructs in the primate brain. We tested a diverse array of viral vectors delivered to the brain and extraocular muscles of macaques and compared three methods for histological assessment of viral-mediated fluorescent transgene expression: epifluorescence (Epi), immunofluorescence (IF), and immunohistochemistry (IHC). Importantly, IF and IHC identified a greater number of transduced neurons compared to Epi. Furthermore, IF and IHC reliably provided enhanced visualization of transgene in most cellular compartments ( i.e. , dendritic, axonal, and terminal fields), whereas the degree of labeling provided by Epi was inconsistent and predominantly restricted to somas and apical dendrites. Because Epi signals are unamplified (in contrast to IF and IHC), Epi may provide a more veridical assessment for the amount of accumulated transgene and, thus, the potential to chemogenetically or optogenetically manipulate neuronal activity. The comparatively weak Epi signals suggest that the current generations of viral constructs, regardless of delivered transgene, are not optimized for primates. This reinforces an emerging viewpoint that viral vectors tailored for the primate brain are necessary for basic research and human gene therapy.


  • Open Access

    Direct comparison of epifluorescence and immunostaining for assessing viral mediated gene expression in the primate brain

    by Tierney B. Daw, Hala G. El-Nahal, Michele A. Basso, Elizabeth J. Jun, Alex R. Bautista, R. Jude Samulski, Marc A. Sommer, Martin O. Bohlen

    Viral vector technologies are commonly used in neuroscience research to understand and manipulate neural circuits, but successful applications of these technologies in non-human primate models have been inconsistent. An essential component to improve these technologies is an impartial and accurate assessment of the effectiveness of different viral constructs in the primate brain. We tested a diverse array of viral vectors delivered to the brain and extraocular muscles of macaques and compared three methods for histological assessment of viral-mediated fluorescent transgene expression: epifluorescence (Epi), immunofluorescence (IF), and immunohistochemistry (IHC). Importantly, IF and IHC identified a greater number of transduced neurons compared to Epi. Furthermore, IF and IHC reliably provided enhanced visualization of transgene in most cellular compartments (i.e., dendritic, axonal, and terminal fields), whereas the degree of labeling provided by Epi was inconsistent and predominantly restricted to somas and apical dendrites. Because Epi signals are unamplified (in contrast to IF and IHC), Epi likely provides a more veridical assessment for the amount of accumulated transgene and, thus, the potential to chemo- or optogenetically manipulate neuronal activity. The comparatively weak Epi signals suggest that the current generations of viral constructs, regardless of delivered transgene, are not optimized for primates. This reinforces an emerging viewpoint that viral vectors tailored for the primate brain are necessary for basic research and human gene therapy.